ClariTrial | Search Clinical Trials

Explore/IRAK4 autoimmune

Status

Phase

9 results for “IRAK4 autoimmune”

Recruiting

A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers

Phase 1Healthy VolunteerHidradenitis SuppurativaAtopic Dermatitis

LT-002-158/Placebo oral tablet(s)

Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.127 participants1 site · ChinaCompletes Mar 2025

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

Phase 1Healthy ParticipantsHealthy SubjectsHealthy Volunteers

BGB-45035Placebo

BeiGene211 participants13 sites · Australia, China, New ZealandCompletes May 2026

Compare CT.gov Full analysis →

UNKNOWN

TLR Polymorphism, ASO and Beta-hemolytic Group A Streptococcus Infections in ADHD: an Observational Study

N/AAttention Deficit-Hyperactivity Disorder

Antistreptolysin O TestAnti-Deoxyribonuclease BTLR, MyD88, IRAK-4 polymorphism+1 more

University of Turin, Italy100 participants1 site · ItalyCompletes Jun 2020

Compare CT.gov Full analysis →

Completed

Results posted

Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate

Phase 2Rheumatoid Arthritis

PF-06650833PlaceboTofacitinib

Pfizer269 participants103 sites · United States, Australia, Bosnia and HerzegovinaCompletes Aug 2018

Compare CT.gov Full analysis →

Terminated

A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis

Phase 2Rheumatoid Arthritis

BGB-45035Placebo

BeiGene49 participants29 sites · ChinaCompletes May 2026

Compare CT.gov Full analysis →

Completed

A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects

Phase 1Rheumatoid Arthritis

TQH3821 tabletsTQH3821 tablets (Placebo)Methotrexate tablets

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.63 participants1 site · ChinaCompletes May 2023

Compare CT.gov Full analysis →

Completed

Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System

N/AAtherosclerosisChronic Granulomatous Disease (CGD)

National Institute of Allergy and Infectious Diseases (NIAID)156 participants1 site · United StatesCompletes Dec 2018

Compare CT.gov Full analysis →

Terminated

A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis

Phase 2Rheumatoid Arthritis

TQH3821 tablets 200 mgTQH3821 tablets matching placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.195 participants34 sites · ChinaCompletes Jan 2025

Compare CT.gov Full analysis →

Completed

Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetic, and Food Effects of ARD-885 Film-coated Tablets in Healthy Chinese Subjects and Patients With Rheumatoid Arthritis

Phase 1Rheumatoid Arthritis (RA)

ARD-885 TabletsARD-885 Placebo Tablet

Artivila (Shenzhen) Innovation Center, Ltd94 participants1 site · ChinaCompletes Aug 2025

Compare CT.gov Full analysis →

1–9 of 9

Explore/IRAK4 autoimmune

Status

Phase

9 results for “IRAK4 autoimmune”

Recruiting

A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers

Phase 1Healthy VolunteerHidradenitis SuppurativaAtopic Dermatitis

LT-002-158/Placebo oral tablet(s)

Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.127 participants1 site · ChinaCompletes Mar 2025

Compare CT.gov Full analysis →

Recruiting

Phase 1Healthy ParticipantsHealthy SubjectsHealthy Volunteers

BGB-45035Placebo

BeiGene211 participants13 sites · Australia, China, New ZealandCompletes May 2026

Compare CT.gov Full analysis →

UNKNOWN

TLR Polymorphism, ASO and Beta-hemolytic Group A Streptococcus Infections in ADHD: an Observational Study

N/AAttention Deficit-Hyperactivity Disorder

Antistreptolysin O TestAnti-Deoxyribonuclease BTLR, MyD88, IRAK-4 polymorphism+1 more

University of Turin, Italy100 participants1 site · ItalyCompletes Jun 2020

Compare CT.gov Full analysis →

Completed

Results posted

Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate

Phase 2Rheumatoid Arthritis

PF-06650833PlaceboTofacitinib

Pfizer269 participants103 sites · United States, Australia, Bosnia and HerzegovinaCompletes Aug 2018

Compare CT.gov Full analysis →

Terminated

A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis

Phase 2Rheumatoid Arthritis

BGB-45035Placebo

BeiGene49 participants29 sites · ChinaCompletes May 2026

Compare CT.gov Full analysis →

Completed

A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects

Phase 1Rheumatoid Arthritis

TQH3821 tabletsTQH3821 tablets (Placebo)Methotrexate tablets

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.63 participants1 site · ChinaCompletes May 2023

Compare CT.gov Full analysis →

Completed

Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System

N/AAtherosclerosisChronic Granulomatous Disease (CGD)

National Institute of Allergy and Infectious Diseases (NIAID)156 participants1 site · United StatesCompletes Dec 2018

Compare CT.gov Full analysis →

Terminated

A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis

Phase 2Rheumatoid Arthritis

TQH3821 tablets 200 mgTQH3821 tablets matching placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.195 participants34 sites · ChinaCompletes Jan 2025

Compare CT.gov Full analysis →

Completed

Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetic, and Food Effects of ARD-885 Film-coated Tablets in Healthy Chinese Subjects and Patients With Rheumatoid Arthritis

Phase 1Rheumatoid Arthritis (RA)

ARD-885 TabletsARD-885 Placebo Tablet

Artivila (Shenzhen) Innovation Center, Ltd94 participants1 site · ChinaCompletes Aug 2025

Compare CT.gov Full analysis →

1–9 of 9